Trial Profile
Phase II Trial for the Treatment of Older Patients With Newly Diagnosed CD19 Positive, Ph/BCR-ABL Negative B-precursor Acute Lymphoblastic Leukemia With Sequential Dose Reduced Chemotherapy and Blinatumomab (EWALL-BOLD)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Jan 2024
Price :
$35
*
At a glance
- Drugs Blinatumomab (Primary) ; Cyclophosphamide; Cytarabine; Dexamethasone; Idarubicin; Mercaptopurine; Methotrexate; Pegaspargase; Vincristine
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Acronyms BOLD; EWALL-BOLD
- 12 Dec 2023 Results assessing dose reduced chemotherapy in sequence with blinatumomab for newly diagnosed older patients with Ph/BCR ABL Negative B-Precursor Adult Lymphoblastic Leukemia, were presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 16 Aug 2022 Planned End Date changed from 1 Jan 2023 to 1 Jan 2024.
- 16 Aug 2022 Planned primary completion date changed from 1 Sep 2022 to 1 Sep 2023.